Skip to content

US · RZLT · BIOTECHNOLOGY

Rezolute, Inc. (RZLT) intrinsic value and stock valuation

$3.92as of 2026-11-21 · Mkt cap 450.65M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rezolute, Inc. DCF and intrinsic value

InvestorsCraft values RZLT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RZLT’s statements →

Rezolute, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94065 rezolutebio.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-74.41M
20122025
Free cash flow
-$-69.08M
20122025
Total equity
$162.1M+85.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-79.89M-$-70.42M-$-55.99M-$-41.84M-$-22.89M
Net income-$-74.41M-$-68.46M-$-51.79M-$-41.06M-$-20.9M
EPSd-$-979.08K-$-1.33M-$-1.01M-$-2.11M-$-2.72M
Operating cash flow-$-69.08M-$-57.37M-$-44.48M-$-39.62M-$-20.44M
Capital expenditure$0.00$0.00-$-150K$0.00$0.00
Free cash flow-$-69.08M-$-57.37M-$-44.63M-$-39.62M-$-20.44M
Total assets$175.5M$132.7M$123.7M$152.4M$42.6M
Total debt$1.61M$2.23M$2.48M$190K$14.4M
Net debt-$-92.49M-$-68.17M-$-13.56M-$-150.22M-$-26.63M
Total equity$162.1M$121M$116.2M$149.5M$26.1M
Cash and short-term investments$167.9M$126.9M$101.9M$150.4M$41.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$10K
Gross profit$0.00$0.00$0.00$0.00-$-10K
Research and development expenses$61.5M$55.7M$43.8M$32.5M$15M
Selling, general and administrative expenses$18.4M$14.7M$12.2M$9.36M$7.91M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$79.9M$70.4M$56M$41.8M$22.9M
Cost and expenses$79.9M$70.4M$56M$41.8M$22.9M
Interest income$5.48M$4.87M$4.21M$80K$60K
Interest expense$0.00$0.00$0.00$1.81M$380K
Depreciation and amortization$30K$40K$30K$10K$10K
Ebitda-$-74.38M-$-68.42M-$-51.76M-$-39.24M-$-20.51M
Operating income-$-79.89M-$-70.42M-$-55.99M-$-41.84M-$-22.89M
Total other income/expenses, net$5.48M$1.96M$4.2M$780K$1.99M
Income before tax-$-74.41M-$-68.46M-$-51.79M-$-41.06M-$-20.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-74.41M-$-68.46M-$-51.79M-$-41.06M-$-20.9M
Weighted average shares outstanding$76M$51.5M$51.2M$18.2M$7.67M
Weighted average diluted shares outstanding$76M$51.5M$51.2M$19.5M$7.67M
Balance sheet
20252024202320222021
Cash and short-term investments$167.9M$126.9M$101.9M$150.4M$41.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$171.2M$128.7M$104.9M$152.1M$42M
Property, plant and equipment, net$1.42M$1.98M$2.19M$170K$420K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$260K$16.5M$0.00$0.00
Total non-current assets$4.34M$4.08M$18.8M$320K$620K
Total assets$175.5M$132.7M$123.7M$152.4M$42.6M
Accounts payable$5.81M$4.9M$3.27M$1.13M$1.03M
Short-term debt$630K$570K$540K$110K$270K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.9M$9.61M$5.2M$2.46M$1.97M
Long-term debt$980K$1.66M$1.94M$80K$14.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.45M$2.13M$2.35M$490K$14.5M
Capital lease obligations$1.61M$2.23M$2.48M$190K$450K
Total liabilities$13.4M$11.7M$7.55M$2.95M$16.5M
Common stock$90K$50K$40K$30K$10K
Retained earnings-$-403.86M-$-329.44M-$-260.99M-$-209.2M-$-168.14M
Accumulated other comprehensive income (loss)-$-10K-$-80K-$-350K$0.00$0.00
Total equity$162.1M$121M$116.2M$149.5M$26.1M
Total investments$73.8M$56.7M$102.3M$0.00$0.00
Total debt$1.61M$2.23M$2.48M$190K$14.4M
Net debt-$-92.49M-$-68.17M-$-13.56M-$-150.22M-$-26.63M
Cash flow statement
20252024202320222021
Net income-$-74.41M-$-68.46M-$-51.79M-$-41.06M-$-20.9M
Depreciation and amortization$30K$40K$30K$10K$10K
Stock-based compensation$7.12M$7.36M$7.27M$3.69M$3.96M
Change in working capital$50K$3.1M$1.02M-$-640K-$-2.12M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.42M$1.08M$2.14M-$-10K$140K
Net cash provided by operating activities-$-69.08M-$-57.37M-$-44.48M-$-39.62M-$-20.44M
Investments in property, plant and equipment$0.00$0.00-$-150K$0.00$0.00
Acquisitions, net$0.00$0.00$101.5M$0.00$0.00
Net cash used for investing activities-$-14.54M$48.7M-$-101.46M$0.00$0.00
Common stock issued$107.3M$49M$12.3M$122.8M$41M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$107.3M$63M$11.6M$149M$51.5M
Net change in cash$23.7M$54.4M-$-134.37M$109.4M$31.1M
Cash at end of period$94.1M$70.4M$16M$150.4M$41.1M
Operating cash flow-$-69.08M-$-57.37M-$-44.48M-$-39.62M-$-20.44M
Capital expenditure$0.00$0.00-$-150K$0.00$0.00
Free cash flow-$-69.08M-$-57.37M-$-44.63M-$-39.62M-$-20.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rezolute, Inc.

        Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

        CEO
        Nevan Charles Elam
        Employees
        68
        Beta
        0.62

        Explore

        Frequently asked questions

        What is the intrinsic value of Rezolute, Inc. (RZLT)?

        InvestorsCraft does not currently publish an intrinsic value for RZLT. How the IC value is calculated.

        Is RZLT undervalued?

        InvestorsCraft does not publish an undervaluation signal for RZLT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.